par Wissing, Karl Martin
;Morelon, E.;Legendre, C;De Pauw, Luc
;LeBeaut, A;Grint, P;Maniscalki, M;Ickx, Brigitte
;Vereerstraeten, Pierre
;Chatenoud, Lucienne;Kreis, H;Goldman, Michel
;Abramowicz, Daniel 
Référence Transplantation, 64, 7, page (999-1006)
Publication Publié, 1997-10






Référence Transplantation, 64, 7, page (999-1006)
Publication Publié, 1997-10
Article révisé par les pairs
Titre: |
|
Auteur: | Wissing, Karl Martin; Morelon, E.; Legendre, C; De Pauw, Luc; LeBeaut, A; Grint, P; Maniscalki, M; Ickx, Brigitte; Vereerstraeten, Pierre; Chatenoud, Lucienne; Kreis, H; Goldman, Michel; Abramowicz, Daniel |
Informations sur la publication: | Transplantation, 64, 7, page (999-1006) |
Statut de publication: | Publié, 1997-10 |
Sujet CREF: | Sciences bio-médicales et agricoles |
MeSH keywords: | Adult |
Antibody Formation | |
Cytokines -- biosynthesis | |
Dose-Response Relationship, Drug | |
Double-Blind Method | |
Drug Administration Schedule | |
Female | |
Fever -- prevention & control | |
Graft Survival -- immunology | |
Humans | |
Immunoglobulin M -- blood | |
Immunosuppressive Agents -- adverse effects | |
Interferon-gamma -- biosynthesis | |
Interleukin-10 -- administration & dosage | |
Interleukin-10 -- blood | |
Interleukin-10 -- therapeutic use | |
Interleukin-2 -- blood | |
Interleukin-8 -- blood | |
Kidney Transplantation -- immunology | |
Male | |
Muromonab-CD3 -- adverse effects | |
Pilot Projects | |
Recombinant Proteins -- administration & dosage | |
Recombinant Proteins -- blood | |
Recombinant Proteins -- therapeutic use | |
Tumor Necrosis Factor-alpha -- biosynthesis | |
Note générale: | Clinical Trial |
Journal Article | |
Randomized Controlled Trial | |
Research Support, Non-U.S. Gov't | |
Langue: | Anglais |
Identificateurs: | urn:issn:0041-1337 |
info:doi/10.1097/00007890-199710150-00012 | |
info:scp/0343329759 | |
info:pmid/9381549 |